Home › Borstkanker › Connecticut › New Haven
Borstkanker klinische studies in New Haven, CT
38 studies voor Borstkanker zoeken deelnemers op locaties in en rond New Haven (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekruterenFase 3
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
A Study of PHST001 in Advanced Solid Tumors
RekruterenFase 1
- Yale Cancer Center, New Haven
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruterenFase 1/2
- Yale Cancer Center, New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruterenFase 2
- Yale Cancer Center, New Haven
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
RekruterenFase 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RekruterenFase 1/2
- Yale University School of Medicine, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RekruterenFase 1
- Yale Cancer Center, New Haven
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RekruterenFase 1
- Yale University - Yale University School of Medicine, New Haven
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
RekruterenFase 1
- Yale Cancer Center, New Haven
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruterenFase 1/2
- Avenzo Therapeutics Recruiting Site, New Haven
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RekruterenFase 3
- Yale Cancer Center ( Site 0060), New Haven
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekruterenFase 3
- Research Site, New Haven
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RekruterenFase 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale University/Yale Cancer Center/Yale School of Medicine, New Haven
- Smilow Cancer Hospital Care Center - North Haven, North Haven · 7 mijl verwijderd
- en nog 2
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekruteren
- Yale Cancer Center, New Haven
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RekruterenFase 3
- Clinical Trial Site, New Haven
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
RekruterenFase 1
- Yale University School Of Medicine, New Haven
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekruterenFase 2
- Yale Cancer Center Clinical Trials Office, New Haven
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RekruterenFase 3
- Yale New Haven Hospital- Yale Cancer Center, New Haven
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
RekruterenFase 1/2
- Yale Cancer Center, New Haven
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RekruterenFase 3
- Smilow Cancer Hospital at Yale New Haven, New Haven
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekruterenFase 3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mijl verwijderd
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mijl verwijderd
- en nog 1
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekruterenFase 1
- Yale Cancer Center, New Haven
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
RekruterenFase 2
- Yale University Cancer Center, New Haven
ATEMPT 2.0: Adjuvant T-DM1 vs TH
RekruterenFase 2
- Yale Cancer Center at Yale University School of Medicine, New Haven
- Smilow Cancer Hospital Care center at North Haven, North Haven · 7 mijl verwijderd
- Smilow Cancer Hospital Care center at Derby, Derby · 8 mijl verwijderd
- en nog 1
Optimizing Surgical Decisions in Young Adults With Breast Cancer
Rekruteren
- Yale Cancer Center, New Haven
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RekruterenFase 3
- Yale Cancer Center - Smilow Cancer Hospital, New Haven
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
RekruterenFase 3
- Yale University, New Haven
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Yale University, Yale Cancer Center, New Haven
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
RekruterenFase 1
- Yale Cancer Center Smilow Cancer Hospital, New Haven
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
RekruterenObservatieonderzoek
- Yale Cancer Center, New Haven
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruterenFase 2
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RekruterenFase 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Smilow Cancer Hospital - North Haven, North Haven · 7 mijl verwijderd
- Smilow Cancer Hospital - Derby, Derby · 8 mijl verwijderd
- en nog 1
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RekruterenFase 3
- Yale-New Haven Hospital Saint Raphael Campus, New Haven
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5 mijl verwijderd
- en nog 4
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekruterenFase 1/2
- Yale University, Yale Cancer Center, New Haven
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
Rekruteren
- Yale University, New Haven
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
RekruterenFase 2
- Yale University, New Haven
The Cancer of the Pancreas Screening-5 CAPS5)Study
RekruterenFase 3
- Yale University, New Haven
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RekruterenFase 1
- Yale University, New Haven
Borstkanker studies in andere steden
- New York City, NY136 studies
- Houston, TX126 studies
- Boston, MA112 studies
- Nashville, TN81 studies
- Los Angeles, CA73 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Queens, NY64 studies
- Durham, NC64 studies
- Chicago, IL59 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Andere studies in New Haven
- Niet-kleincellige longkanker41 studies
- Kanker (alle vormen)33 studies
- Metastatische kanker23 studies
- Longkanker22 studies
- Plaveiselcelcarcinoom van hoofd en hals22 studies
- Eierstokkanker21 studies
- Colorectale kanker20 studies
- Prostaatkanker20 studies
- Acute myeloïde leukemie17 studies
- Alcoholgebruiksstoornis (AUD)17 studies
- Opioïde-overdosering17 studies
- Aldermeesklierkanker16 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.